This phase 1b open label, dose-escalating investigation study is to evaluate the dose
dependent initial efficacy of the use of MT218 injection for biomarker targeted MR
molecular imaging (MRMI) of prostate cancer in patients scheduled for radical
prostatectomy.
Additional locations may be listed on ClinicalTrials.gov for NCT06262139.
Locations matching your search criteria
United States
Georgia
Atlanta
Emory University Hospital/Winship Cancer InstituteStatus: Active
Name Not Available
Phase 1b open label, single-arm, dose-escalating investigation of safety and efficacy of
a gadolinium (Gd) and peptide based MRI contrast agent (MT218) as an extradomain-B
fibronectin (EDB-FN) targeted molecular MR contrast agent to detect aggressive prostate
cancer with comparison of its results with the standard-of-care mutliparametic MRI
(mpMRI) and PSMA PET/CT and histopathology validation in preprostatectomy patients
diagnosed with prostate cancer in their clinical care.
Lead OrganizationSongqi Gao
Principal InvestigatorDavid Michael Schuster